Diabetic nephropathy: Aldosterone breakthrough in patients on an ACEI

@article{Nakagawa2010DiabeticNA,
  title={Diabetic nephropathy: Aldosterone breakthrough in patients on an ACEI},
  author={T. Nakagawa},
  journal={Nature Reviews Nephrology},
  year={2010},
  volume={6},
  pages={194-196}
}
  • T. Nakagawa
  • Published 2010
  • Medicine
  • Nature Reviews Nephrology
  • Blockade of the renin–angiotensin system has beneficial effects in patients with diabetic nephropathy; however, this treatment can induce aldosterone breakthrough and thus become ineffective. New data indicate that aldosterone breakthrough develops even when maximal doses of an angiotensin-converting-enzyme inhibitor are administered to patients with diabetic nephropathy. 
    1 Citations
    Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications
    • 98

    References

    SHOWING 1-10 OF 18 REFERENCES
    Avosentan reduces albumin excretion in diabetics with macroalbuminuria.
    • 207
    • PDF
    Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    • M. Weir, M. Rolfe
    • Medicine
    • Clinical journal of the American Society of Nephrology : CJASN
    • 2010
    • 148
    • PDF
    Resistant hypertension and hyperaldosteronism
    • 31